Analysis of an independent tumor suppressor locus telomeric to Tp53 suggested Inpp5k and Myo1c as novel tumor suppressor gene candidates in this region

BMC Genetics

Volumn 16, Issue 1, 2015, Pages

  Hedberg Oldfors, Carola ^a   Dios, Diego Garcia ^a   Linder, Anna ^a   Visuttijai, Kittichate ^a,b   Samuelson, Emma ^a   Karlsson, Sandra ^b   Nilsson, Staffan ^c   Behboudi, Afrouz ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF SKÖVDE   (Sweden)

^c CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

17p13.3; Endometrial carcinoma; Hic1; Inpp5k; Myo1c; RNO10q24 q25; Skip; Tp53

Indexed keywords

DECITABINE; HYPERMETHYLATED IN CANCER 1 PROTEIN; INOSITOL POLYPHOSPHATE 5 PHOSPHATASE K; MYOSIN; MYOSIN 1C; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; SYNAPTOJANIN; TRICHOSTATIN A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; AZACITIDINE; HYDROXAMIC ACID; INOSITOL POLYPHOSPHATE 5 PHOSPHATASE; MYO1C PROTEIN, HUMAN; MYOSIN I; PHOSPHATASE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL SURVIVAL; CHROMOSOME 17P; CONTROLLED STUDY; CRK GENE; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; EMBRYO; ENDOMETRIUM CARCINOMA; EPIGENETICS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; GENE EXPRESSION RESTORATION ASSAY; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENETIC ANALYSIS; HAPLOINSUFFICIENCY; HIC1 GENE; INPP5K GENE; MYO1C GENE; NONHUMAN; ONCOGENE; OVCA1 GENE; OVCA2 GENE; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RPA1 GENE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SKIP GENE; TELOMERE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; GENE LOCUS; GENETICS; HUMAN;

RATTUS;

ANIMALS; AZACITIDINE; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; GENETIC LOCI; HUMANS; HYDROXAMIC ACIDS; INOSITOL POLYPHOSPHATE 5-PHOSPHATASES; MYOSIN TYPE I; PHOSPHORIC MONOESTER HYDROLASES; RATS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84937029410     PISSN: None     EISSN: 14712156     Source Type: Journal    
DOI: 10.1186/s12863-015-0238-4     Document Type: Article

References (42)

1. Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumour heterogeneity. Journal of Molecular Medicine-Jmm. 1997;75:429-39.
2. Bova GS, Isaacs WB. Review of allelic loss and gain in prostate cancer. World Journal of Urology. 1996;14:338-46.
3. Kaneko Y, Homma C, Maseki N, Sakurai M, Hata J. Correlation of Chromosome-Abnormalities with Histological and Clinical-Features in Wilms and Other Childhood Renal Tumors. Cancer Research. 1991;51:5937-42.
4. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood. 1998;91:616-22.
5. Whibley C, Pharoah PDP, Hollstein M. p53 polymorphisms: cancer implications. Nature Reviews Cancer. 2009;9:95-107.
6. Guan XY, Sham JS, Tai LS, Fang Y, Li H, Liang Q. Evidence for another tumor suppressor gene at 17p13.3 distal to TP53 in hepatocellular carcinoma. Cancer genetics and cytogenetics. 2003;140:45-8.
7. Konishi H, Sugiyama M, Mizuno K, Saito H, Yatabe Y, Takahashi T, et al. Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at distal 17p13.3 in human lung cancer. Oncogene. 2003;22:1892-905.
8. Roncuzzi L, Brognara I, Baiocchi D, Amadori D, Gasperi-Campani A. Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer. Oncology reports. 2005;14:471-4.
9. Sarkar C, Chattopadhyay P, Ralte AM, Mahapatra AK, Sinha S. Loss of heterozygosity of a locus in the chromosomal region 17p13.3 is associated with increased cell proliferation in astrocytic tumors. Cancer Genetics and Cytogenetics. 2003;144:156-64.
10. Nordlander C, Karlsson S, Karlsson A, Sjoling A, Winnes M, Klinga-Levan K, et al. Analysis of chromosome 10 aberrations in rat endometrial cancer-evidence for a tumor suppressor locus distal to Tp53. Int J Cancer. 2007;120:1472-81.
11. Behboudi A, Levan G, Hedrich HJ, Klinga-Levan K. High-density marker loss of heterozygosity analysis of rat chromosome 10 in endometrial adenocarcinoma. Genes, Chromosomes and Cancer. 2001;32:330-41.
12. Helou K, Walentinsson A, Beckmann B, Johansson A, Hedrich HJ, Szpirer C, et al. Analysis of genetic changes in rat endometrial carcinomas by means of comparative genomic hybridization. Cancer Genet Cytogenet. 2001;127:118-27.
13. Nordlander C, Behboudi A, Levan G, Levan KK. Allelic imbalance on chromosome 10 in rat endometrial adenocarcinomas. Cancer Genet Cytogenet. 2005;156:158-66.
14. Chen L, Nordlander C, Behboudi A, Olsson B, Levan KK. Deriving evolutionary tree models of the oncogenesis of endometrial adenocarcinoma. Int J Cancer. 2007;120:292-6.
15. Behboudi A, Hedrich HJ, Szpirer C, Levan G, Klinga-Levan K. Loss of heterozygosity analysis of rat chromsome 10 in endometrial adenocarcinoma. Rat Genome. 2000;6:77.
16. Hamta A, Adamovic T, Helou K, Levan G. Cytogenetic aberrations in spontaneous endometrial adenocarcinomas in the BDII rat model as revealed by chromosome banding and comparative genome hybridization. Cancer Genetics and Cytogenetics. 2005;159:123-8.
17. Kobashigawa Y, Sakai M, Naito M, Yokochi M, Kumeta H, Makino Y, et al. Structural basis for the transforming activity of human cancer-related signaling adaptor protein CRK. Nature Structural & Molecular Biology. 2007;14:503-10.
18. Nishihara H, Tanaka S, Tsuda M, Oikawa S, Maeda M, Shimizu M, et al. Molecular and immunohistochemical analysis of signaling adaptor protein Crk in human cancers. Cancer Letters. 2002;180:55-61.
19. Wang L, Tabu K, Kimura T, Tsuda M, Linghu H, Tanino M, et al. Signaling adaptor protein Crk is indispensable for malignant feature of glioblastoma cell line KMG4. Biochemical and Biophysical Research Communications. 2007;362:976-81.
20. Knudson AG. A two-mutation model for human cancer. Advances in Viral Oncology. 1987;7:1-7.
21. Makos M, Nelkin BD, Reiter RE, Gnarra JR, Brooks J, Isaacs W, et al. Regional DNA Hypermethylation at D17s5 Precedes 17p Structural-Changes in the Progression of Renal Tumors. Cancer Research. 1993;53:2719-22.
22. Morton RA, Watkins JJ, Bova GS, Wales MM, Baylin SB, Isaacs WB. Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue. Journal of Urology. 1996;156:512-6.
23. Astle MV, Seaton G, Davies EM, Fedele CG, Rahman P, Arsala L, et al. Regulation of phosphoinositide signaling by the inositol polyphosphate 5-phosphatases. Iubmb Life. 2006;58:451-6.
24. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews Genetics. 2006;7:606-19.
25. Ijuin T, Takenawa T. SKIP negatively regulates insulin-induced GLUT4 translocation and membrane ruffle formation. Molecular and Cellular Biology. 2003;23:1209-20.
26. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. Journal of Biological Chemistry. 1998;273:13375-8.
27. Bond LM, Brandstaetter H, Kendrick-Jones J, Buss F. Functional roles for myosin 1c in cellular signaling pathways. Cell Signal. 2013;25:229-35.
28. Brandstaetter H, Kendrick-Jones J, Buss F. Myo1c regulates lipid raft recycling to control cell spreading, migration and Salmonella invasion. J Cell Sci. 2012;125:1991-2003.
29. Oh H, Kim H, Shin B, Lee KH, Yeo MG, Song WK. Interaction of crk with Myosin-1c participates in fibronectin-induced cell spreading. Int J Biol Sci. 2013;9:778-91.
30. Hokanson DE, Ostap EM. Myo1c binds tightly and specifically to phosphatidylinositol 4,5-bisphosphate and inositol 1,4,5-trisphosphate. Proc Natl Acad Sci U S A. 2006;103:3118-23.
31. Bose A, Guilherme A, Robida SI, Nicoloro SM, Zhou QL, Jiang ZY, et al. Glucose transporter recycling in response to insulin is facilitated by myosin Myo1c. Nature. 2002;420:821-4.
32. Holman GD, Sakamoto K. Regulating the Motor for GLUT4 Vesicle Traffic. Cell Metabolism. 2008;8:344-6.
33. Yip MF, Ramm G, Larance M, Hoehn KL, Wagner MC, Guilhaus M, et al. CaMKII-Mediated Phosphorylation of the Myosin Motor Myolc Is Required for Insulin-Stimulated GLUT4 Translocation in Adipocytes. Cell Metabolism. 2008;8:384-98.
34. Nishioka M, Kohno T, Tani M, Yanaihara N, Tomizawa Y, Otsuka A, et al. MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer. Proc Natl Acad Sci U S A. 2002;99:12269-74.
35. Taki T, Akiyama M, Saito S, Ono R, Taniwaki M, Kato Y, et al. The MYO1F, unconventional myosin type 1 F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11, 19 and 22. Oncogene. 2005;24:5191-7.
36. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature reviews Cancer. 2009;9:550-62.
37. Deerberg F, Kaspareit J. Endometrial carcinoma in BDII/Han rats: model of a spontaneous hormone-dependent tumor. Journal of the National Cancer Institute. 1987;78:1245-51.
38. Kaspareit-Rittinghausen J, Deerberg F, Rapp K. Mortality and incidence of spontaneous neoplasms in BDII/Han rats. Zeitschrift für Versuchstierkunde. 1987;30:209-16.
39. Roshani L, Mallon P, Sjostrand E, Wedekind D, Szpirer J, Szpirer C, et al. Genetic analysis of susceptibility to endometrial adenocarcinoma in the BDII rat model. Cancer Genetics and Cytogenetics. 2005;158:137-41.
40. Roshani L, Wedekind D, Szpirer J, Taib Z, Szpirer C, Beckman B, et al. Genetic identification of multiple susceptibility genes involved in the development of endometrial carcinoma in a rat model. International Journal of Cancer. 2001;94:795-9.
41. Samuelson E, Hedberg C, Nilsson S, Behboudi A. Molecular classification of spontaneous endometrial adenocarcinomas in BDII rats. Endocr Relat Cancer. 2009;16:99-111.
42. Caren H, Fransson S, Ejeskar K, Kogner P, Martinsson T. Genetic and epigenetic changes in the common Ip36 deletion in neuroblastoma tumours. British Journal of Cancer. 2007;97:1416-24.